Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

AIM Vaccine Co Ltd

AIM Vaccine Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)8.36
  • Today's Change0.85 / 11.32%
  • Shares traded24.69m
  • 1 Year change-5.43%
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024 08:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AIM Vaccine Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of vaccine. The Company's products mainly include recombinant hepatitis B vaccine, human rabies vaccine, inactivated hepatitis A vaccine, mumps vaccine, inactivated hemorrhagic fever with renal syndrome vaccine and MPSV4. The Company's products are mainly used for the treatment of hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, rabies and meningococcal diseases. The Company's vaccine candidates include messenger RNA (mRNA) corona virus disease 2019 (COVID-19) vaccine, inactivated COVID-19 vaccine, broad-spectrum COVID-19 vaccine, PCV13, PPSV23 and MCV4. The Company principally conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)1.29bn
  • Net income in HKD-1.30bn
  • Incorporated2011
  • Employees1.56k
  • Location
    AIM Vaccine Co Ltd25/FBuilding A, 91 Jianguo Road, ChaoyangBEIJING 110000ChinaCHN
  • Phone+86 1 085950689
  • Fax+86 1 085950063
  • Websitehttps://www.aimbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shandong Boan Biotechnology Co Ltd786.30m67.51m4.88bn777.0068.723.0534.086.210.13260.13261.542.990.30691.102.60967,157.302.63--3.43--74.10--8.59--1.034.010.3369--19.80--64.02------
Tong Ren Tang Technologies Co Ltd7.51bn710.87m6.54bn4.01k9.210.84444.600.87120.5550.5555.876.050.50260.98815.221,831,768.007.427.6811.6912.3240.9743.5014.7616.112.30--0.196839.9413.046.011.25-2.73-22.26-0.0089
Sihuan Pharmaceutical Holdings Group Ltd1.92bn-41.29m6.80bn2.65k--1.41--3.55-0.0045-0.00450.20650.51820.15060.8943.90667,311.90-1.77-6.85-2.68-9.1065.9175.81-11.78-36.231.50--0.181---14.70-8.6097.23--0.9325--
Beijing Tong Ren Tang Chinese Medicine1.38bn494.14m6.81bn779.0013.771.7911.014.940.59030.59031.644.550.32840.35543.621,725,133.0012.7216.7114.0918.7572.0669.8838.7240.729.55--0.032768.87-11.910.1459-16.33-1.43-16.307.49
Consun Pharmaceutical Group Ltd2.99bn913.63m6.99bn3.18k7.301.736.992.341.131.133.714.790.52092.0012.89956,784.4015.9712.0423.2419.2574.2274.5530.6624.892.80--0.114440.8410.717.0314.8811.01-22.9318.43
China Shineway Pharmaceutical Group Ltd4.59bn1.21bn7.61bn3.23k5.760.94945.461.661.601.606.089.690.44761.285.261,336,654.0011.768.0315.479.7775.2174.5526.2717.873.14--0.045736.2914.3211.9434.1413.890.639612.88
Yichang Hec Changjiang Pharmactcl Co Ltd6.05bn1.80bn7.76bn4.89k4.310.823.711.282.052.056.8810.760.42722.503.741,310,494.0011.698.0317.2711.8178.9079.9727.3720.801.9350.790.212615.8168.0820.182,501.2416.15-11.50--
AIM Vaccine Co Ltd1.29bn-1.30bn9.10bn1.56k--2.38--7.03-1.07-1.071.073.160.14620.63251.10796,494.10-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Everest Medicines Ltd457.20m-1.15bn10.25bn520.00--2.10--22.42-3.57-3.571.4215.020.07565.233.221,058,327.00-19.03-30.52-20.21-33.1475.74---251.64-5,745.254.62--0.1119--884.46---241.50--4.65--
Luye Pharma Group Ltd6.90bn841.60m10.50bn5.23k12.470.7386.201.520.22370.22371.833.780.2362.443.021,308,626.003.112.805.474.4568.7370.5313.1810.391.203.140.410311.822.703.50-11.94-16.39-14.05--
SSY Group Ltd6.47bn1.37bn11.15bn5.80k8.211.546.101.720.45930.45932.182.440.54182.753.071,155,141.0011.5410.5114.8814.0354.3958.7221.3018.622.0628.650.32338.560.45059.1017.447.663.9413.56
Shanghai Henlius Biotech Inc6.16bn756.26m11.82bn3.55k15.674.2010.191.921.391.3911.295.180.57641.906.821,694,066.007.07-8.5914.25-14.1473.2371.7712.27-27.370.3297.600.6113--67.82273.51178.53--49.14--
China Traditional Chinese Med Hldg CoLtd18.79bn1.00bn11.99bn17.72k11.960.51345.240.63780.1990.1993.734.640.4531.541.821,086,100.002.624.604.017.0749.8657.075.779.771.517.390.180817.3526.699.9968.11-2.24-12.75--
Data as of Nov 01 2024. Currency figures normalised to AIM Vaccine Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

6.22%Per cent of shares held by top holders
HolderShares% Held
China Merchants Wealth Asset Management Ltd.as of 09 Oct 202423.53m4.78%
GF Fund Management Co., Ltd.as of 30 Jun 20243.52m0.72%
China Asset Management Co., Ltd.as of 30 Jun 20241.57m0.32%
BlackRock Fund Advisorsas of 03 Oct 20241.04m0.21%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024212.60k0.04%
Dimensional Fund Advisors LPas of 31 Jul 2024180.20k0.04%
China Southern Asset Management Co., Ltd.as of 30 Jun 2024168.40k0.03%
TIAA-CREF Investment Management LLCas of 31 Aug 2024166.60k0.03%
SSgA Funds Management, Inc.as of 03 Oct 2024124.80k0.03%
China Universal Asset Management Co., Ltd.as of 30 Jun 202499.00k0.02%
More ▼
Data from 30 Jun 2024 - 09 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.